Fed. Circ. Grants Last-Minute Pause Of ITC's Botox Rival Ban
South Korean-based Daewoong Pharmaceuticals can keep its low-cost version of Allergan's Botox treatment on the market while the Federal Circuit considers whether it should pause the U.S. International Trade Commission's import...To view the full article, register now.
Already a subscriber? Click here to view full article